News · United States · 2026-06-17

FTC and four states sue WPATH over deceptive claims about pediatric medical transition

The Federal Trade Commission, joined by Alaska, Iowa, Nebraska and Texas, has filed a federal complaint against the World Professional Association for Transgender Health. The allegation: WPATH's Standards of Care misled parents about the necessity, safety and effectiveness of puberty blockers, cross-sex hormones and surgery in minors.

The four core allegations

The complaint, filed on 17 June 2026, rests on four factual allegations against WPATH. Each stands on its own; together they form a pattern that, in the FTC's view, amounts to consumer deception.

1. Removing age limits in SOC8 (2022)

In its Standards of Care 8, WPATH eliminated all age limits for mastectomy and penile removal in pediatric patients. The complaint alleges that this change was not based on medical evidence. It was the outcome of a political-strategic lobbying process — as previously documented in the WPATH Files — not of any scientific evaluation.

2. Failure to disclose side effects

The complaint enumerates side effects that WPATH allegedly failed to disclose to parents and patients. Cross-sex hormones can cause mood disturbances, vocal pain and limitations, pelvic pain, clitoral discomfort, vaginal pain, inability to orgasm, incontinence and erectile pain. These risks appear verbatim in the complaint — as facts WPATH should have disclosed, but did not.

3. The "lifesaving" frame without evidence

In several instances, the complaint describes, parents seeking help for their children were asked by clinicians whether they "would rather have a live daughter or a dead son." That framing relies on WPATH's representation that pediatric medical transition services are "lifesaving." The FTC states explicitly that there is no competent and reliable scientific evidence that these interventions reduce the risk of suicide — a finding consistent with the Cass Review, SBU and COHERE evaluations.

4. "Medically necessary" as an insurance lever

WPATH presents its recommendations as "consensus-based expert opinion" and labels nearly every pediatric transition service as "medically necessary." According to the complaint, that label is not supported by competent and reliable scientific evidence, but functions as a lever to compel insurers to pay — directly aligned with the financial interests of WPATH members.

Why this matters for the Dutch track

The Dutch Kwaliteitsstandaard Transgenderzorg refers directly to WPATH's Standards of Care. Amsterdam UMC has historically delivered the Dutch Protocol as the scientific basis on which WPATH built its international position. The 2024 Vrouenraets paper in BMC Medical Ethics conceded — from within that center itself — that the empirical underpinning for effectiveness falls short.

An American federal complaint adds a new legal dimension to that picture. When a regulator in the United States holds that WPATH's core claims are misleading, a Dutch clinician relying on WPATH SOC can no longer use that reference unchallenged in a later proceeding. The very report that grounds the case file is now itself in the dock.

Continue in this dossier